Amorfix to Develop a Blood Test for ALS

Amorfix Life Sciences, a Canadian biotech company focused on diagnostics and therapeutics for misfolded protein diseases, announced that it is developing a diagnostic blood test for ALS based on the finding that misfolded SOD1 is present in the blood of ALS patients. The company plans to capitalize on this discovery and existing scientific expertise to develop a simple blood test that measures misfolded SOD1 in blood. Amorfix is also partnering with Biogen Idec on a potential ALS therapy.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail